Spyre Therapeutics (SYRE) Equity Average (2016 - 2025)
Historic Equity Average for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to $455.4 million.
- Spyre Therapeutics' Equity Average rose 2979.56% to $455.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.4 million, marking a year-over-year increase of 2979.56%. This contributed to the annual value of $350.9 million for FY2024, which is 19951.22% up from last year.
- Per Spyre Therapeutics' latest filing, its Equity Average stood at $455.4 million for Q3 2025, which was up 2979.56% from $469.2 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Equity Average ranged from a high of $500.2 million in Q1 2025 and a low of -$226.4 million during Q3 2023
- Moreover, its 5-year median value for Equity Average was $110.6 million (2021), whereas its average is $161.3 million.
- Its Equity Average has fluctuated over the past 5 years, first crashed by 39844.11% in 2023, then skyrocketed by 147685.14% in 2024.
- Spyre Therapeutics' Equity Average (Quarter) stood at $93.0 million in 2021, then crashed by 36.64% to $58.9 million in 2022, then plummeted by 152.08% to -$30.7 million in 2023, then soared by 1476.85% to $422.6 million in 2024, then grew by 7.77% to $455.4 million in 2025.
- Its Equity Average stands at $455.4 million for Q3 2025, versus $469.2 million for Q2 2025 and $500.2 million for Q1 2025.